Navigation Links
Dr. William McGuire, Former UnitedHealth Group CEO, Joins Rebiotix Inc. Board of Directors
Date:5/1/2013

ROSEVILLE, Minn., May 1, 2013 /PRNewswire/ -- William "Bill" McGuire, M.D., former chairman and CEO of UnitedHealth Group, has joined the board of directors of Rebiotix Inc.

The Roseville, Minn.-based biotechnology company is pioneering a practical and non-antibiotic treatment for recurrent Clostridium difficile infection (CDI) known as Microbiota Restoration Therapy (MRT). CDI has been linked to 14,000 deaths annually in the US, and has become the most common healthcare-associated infection in some parts of the country, surpassing Methicillin-resistant Staphylococcus aureus (MRSA) infections. There are few evidence-based approaches to the treatment of multiple recurrent CDI.

"CDI is a major health problem with very significant implications in terms of morbidity, mortality and health resource utilization, and there are a lot of indicators that MRT could be a meaningful solution," says McGuire, who joined the Rebiotix board of directors on March 1. "The company has re-engineered fecal transplants and has brought the technology far enough down the path that it's not a pie-in-the-sky idea. There is the potential for real effectiveness here, and it's quite novel as well. It is very exciting."

Studies have shown that fecal transplant, the predecessor to MRT, is highly successful in curing recurrent CDI. However, it involves time-consuming donor screening and unappealing fecal sample preparation processes for the physician. MRT is designed to solve those problems.

The development of MRT has been spurred on by the Human Microbiome Project, a national research initiative which focused on the relationship between disease and changes in human microbial communities.

McGuire is best known for his tenure as chairman and chief executive officer of UnitedHealth Group from 1991 to 2006. He joins Rebiotix CEO Lee Jones and two other board members: longtime
'/>"/>

SOURCE Rebiotix Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Masimo to Present at William Blair & Company 32nd Annual Growth Stock Conference
2. Stereotaxis Appoints William C. Mills III as Chairman of Board of Directors
3. Perrigo Company To Present At The William Blair Growth Stock Conference
4. Covance To Present At The William Blair 32nd Annual Growth Stock Conference
5. Lippincott Williams & Wilkins Launches Electronic Health Record (EHR) Learning Tool to Help Future Nurses Prepare for New Practice Requirements
6. IRIDEX Appoints Chairman William M. Moore as Interim President & CEO
7. Aushon BioSystems Appoints Bill Williams Vice President of Sales
8. Aushon BioSystems ernennt Bill Williams zum neuen Vice President of Sales
9. BD Announces Appointment of William A. Kozy as Chief Operating Officer
10. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
11. Huntington Memorial Hospital Elects Paul Johnson, Deborah Williams to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today announced ... platform during a special event at the company,s office ... on September 5, 2014. The event, which will start ... ApolloDx website, www.apollodx.com .    "We ... said Jared Bauer , Co-Founder and Managing Partner ...
(Date:8/20/2014)... 2014 Trovagene, Inc. (NASDAQ:   TROV), a ... from two clinical studies will be presented at the ... diagnostic test for the detection of high risk strains ... to take place in Seattle ... Additionally, a new U.S. patent was issued earlier this ...
(Date:8/20/2014)... , August 20, 2014 ... Conducted in the US  KalVista Pharmaceuticals ("KalVista"), ... edema (DME), today announces that it has begun a ... plasma kallikrein inhibitor, KVD001, for the treatment of DME. ... of the Beetham Eye Institute, Joslin Diabetes Center; Harvard ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... announces that a new market research report is ... Degeneration Therapy Area Pipeline Report ... Therapy Area Pipeline Report contains detailed information on ... insight into the pipeline status of macular degeneration ...
... Allscripts (NASDAQ: MDRX ) announced today that it ... March 31, 2011 after the stock market closes on Thursday, ... and webcast to discuss the company,s earnings and other information ... (Logo: http://photos.prnewswire.com/prnh/20100901/CG58147LOGO ) More ...
Cached Medicine Technology:Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 2Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 2Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 4
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 ... and other minor infections might trigger a strong but brief ... study suggests. Just five out of 100,000 children a ... Heather Fullerton, lead author of the study and a professor ... Francisco Benioff Children,s Hospital. "It seems infections play a role ...
(Date:8/20/2014)... Kathleen Doheny HealthDay Reporter ... reconstruction after a mastectomy has long been an option, but ... women choose it. "The most common reasons women didn,t ... weren,t interested in more surgery or they were focused on ... of breast surgery at Memorial Sloan Kettering Cancer Center, in ...
(Date:8/20/2014)... A common approach to treating kidney failure by ... survival chances for people who suddenly developed the condition, ... of Pittsburgh School of Medicine. , Their findings, published ... acute hemodialysis, an aggressive method that is standardly used ... a definitive benefit to the patient. , "Our findings ...
(Date:8/20/2014)... approach to treating cancer - using Botox. A study ... Translational Medicine shows that cancer growth could be ... are linked to cancer stem cells. The approach thus ... treatment cheap, safe and efficient. The researchers have thus ... start testing on humans. , The nervous system is ...
(Date:8/20/2014)... Pittsburgh, PA (PRWEB) August 20, 2014 ... waste products from the blood did not improve survival ... an analysis led by experts at the University ... findings, published online today in the journal PLOS ... is standardly used for people with sudden kidney failure, ...
Breaking Medicine News(10 mins):Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Treating gastric cancer -- with Botox 2Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2
... Pakistan Tuesday enhanced their cooperation in the crucial area ... polio and avian flu. // ,"The ... exchanged ideas on management of avian influenza," external affairs ... the first meeting of the India-Pakistan Joint Commission technical-level ...
... over reports of malarial deaths in Jharkhand's Sahibganj district, the ... // , today urged the health department to step up ... at the earliest direct its medical teams to find out ... disease has afflicted several people in the district, JD(U) spokesman ...
... A recent study has revealed that the place of birth determines ... far lower life expectancy than those born in south east England ... city was found to be 69.3 it was found to be ... conducted the research and it has ranked the 10 best and ...
... insisted that hospital consultants who are not referring patients to ... concerns that the NTPF has only seen a fraction of ... ,NTPF chairman Pat O'Byrne commented that there was no ... months for a surgical procedure. ,"There's no doubt ...
... Boards (DHBs), striking junior doctors returned to hospital calling off their ... doctor's union - Resident Doctors' Association (RDA) and the DHBs met ... planned to meet on Thursday for confirming the results. ... lasted for 5 days. , ,But unfortunately last time ...
... Carolina have found that very few of the patients ... resulted due to chronic obstructive pulmonary disease (COPD) such ... and management. ,Explaining that ideal care means ... the treatment guidelines for this condition and none of ...
Cached Medicine News:Health News:Life Expectancy Determined by Place of Birth 2Health News:COPD Patients In US Are Not Receiving 'Ideal Care' 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: